Year,Observation status,Unit multiplier,Nature of data points,Frequency of observation,Reporting type,SERIES,Reference area,UNIT_MEASURE,Value
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,94.1
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.3
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.4
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.5
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.1
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.2
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.9
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,95.8
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,96.1
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,93.4
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,94.5
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Kyrgyzstan,Percent,94.351083
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,93.4
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.8
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,95.4
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.8
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.3
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,97.7
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.9
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.1
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.7
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,96.6
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,Percent,98.322619
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,93.6
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.6
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,94.2
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.9
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,97.8
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,94.8
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,96.1
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,95.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,93.8
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,96.1
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,Percent,90.174029
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,93.9
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.2
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.3
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,97.2
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,93.6
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,96.9
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,97.3
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,91.3
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,98.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.9
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,96.1
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,95.0
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,Percent,94.575714
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,94.4
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.2
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.3
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,96.8
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,95.5
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.4
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,98.0
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.6
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.2
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,96.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,94.8
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,Percent,97.59292
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,94.4
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,94.5
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.1
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.5
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,93.6
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,93.0
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,96.2
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,98.3
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,97.1
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,98.5
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,96.6
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,95.8
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,Percent,99.33564
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.0
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.8
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,94.6
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.8
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.3
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.0
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.2
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,93.4
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,96.8
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.2
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,93.1
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,95.3
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,Percent,92.698706
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,94.0
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,95.5
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,95.5
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.3
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.8
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.6
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.3
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,96.0
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,97.5
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,91.8
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,92.5
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,Percent,91.652622
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,95.0
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,94.9
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,95.5
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.8
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.4
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,97.2
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,96.6
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,93.7
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,94.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,90.5
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,86.5
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,90.3
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),Percent,92.018905
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.7
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.4
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.7
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,98.5
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,99.2
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.0
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,97.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,96.7
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,98.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.2
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),Percent,95.586032
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.8
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,99.1
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.9
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.3
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.2
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.7
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,98.666102
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,95.6
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,99.1
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.0
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,94.7
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,96.244215
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Kyrgyzstan,Percent,97.245414
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.2
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.0
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,97.2
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,95.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,100.0
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,98.9
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,97.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,99.9
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,98.7
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,92.454654
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,Percent,98.254513
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,97.8
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.2
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,98.3
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,98.3
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,100.0
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.0
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,99.6
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,91.7
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,100.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,95.7
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,88.8
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,93.49863
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,Percent,93.035179
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.0
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.7
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.7
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,99.2
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,96.9
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.7
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,97.4
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.6
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,98.9
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,97.7
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,95.1
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,96.51199
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,Percent,97.67698
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.4
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.1
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.9
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,99.5
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,96.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.6
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.3
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.7
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.1
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.1
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,97.646444
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,Percent,98.140747
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,98.9
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.5
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.8
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.7
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,94.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.6
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,97.9
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.1
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.2
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,96.8
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,98.10916
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,Percent,99.619945
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.6
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,99.2
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.6
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.1
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.8
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.7
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,94.3
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.1
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,97.0
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,95.6
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,98.413291
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,Percent,95.974889
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,99.1
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.4
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,98.7
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.4
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.1
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.4
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,99.3
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.5
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,98.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,95.0
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,96.3
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,97.43813
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,Percent,99.450649
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.8
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.9
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,98.6
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.0
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,97.4
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,97.7
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,98.4
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,95.6
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,99.8
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,95.1
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,91.7
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,96.281062
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),Percent,96.444387
2007,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.8
2008,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.9
2009,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.2
2010,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,97.4
2011,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.7
2012,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.1
2013,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,98.7
2014,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.9
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.7
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,96.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,97.7
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,99.425085
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),Percent,97.981883
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,96.8
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,97.2
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,94.2
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,92.0
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Kyrgyzstan,Percent,95.083643
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,97.3
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,99.3
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,96.3
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,94.6
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,Percent,99.597512
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,97.3
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,95.9
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,94.5
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,93.8
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,Percent,90.089857
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,98.2
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,96.4
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,96.3
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,95.0
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,Percent,94.992818
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,96.8
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,96.7
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,97.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,95.1
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,Percent,97.283381
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,96.3
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,98.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,97.2
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,92.1
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,Percent,98.41451
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,97.2
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,96.1
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,94.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,96.0
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,Percent,94.297841
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,97.6
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,98.7
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,92.6
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,92.1
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,Percent,94.916128
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,95.0
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,94.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,90.4
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,83.4
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),Percent,93.823491
2015,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,97.9
2016,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,96.8
2017,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,90.0
2018,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,93.9
2019,Normal value,Units,Country Data,Annual,National,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),Percent,95.896254
